In the Hippo pathway-proficient cell line HepG2, TEAD inhibition led to a partial reduction in AMOTL2, CTGF, and CYR61 mRNA expression, as expected and consistent with the partial efficacy we observed in Hippo-defective mesothelioma cell lines (Figure 3A). Here, AMOTL2 is linked to mesothelioma.